MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-09-2026
Anavex Life Sciences Corp. Operating Cash Flow 2011-2026 | AVXL
Annual Operating Cash Flow Anavex Life Sciences Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39 M | -30.8 M | -27.8 M | -24.2 M | -30.4 M | -21.3 M | -18.5 M | -12.6 M | -9.02 M | -9.24 M | -4.23 M | -2.66 M | -778 K | -1.69 M | -3.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -778 K | -39 M | -15.7 M |
Quarterly Operating Cash Flow Anavex Life Sciences Corp.
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.15 M | - | - | - | -12.1 M | - | - | - | -7.32 M | - | - | - | -5.79 M | -20.2 M | - | - | -3.5 M | -22.7 M | -15.2 M | - | -7.87 M | -15 M | -11 M | -7.87 M | -5.73 M | -16 M | -8.49 M | -5.73 M | -4.16 M | -8.53 M | -6.44 M | -4.16 M | -3.62 M | -6.83 M | -3.85 M | -3.62 M | -3.15 M | - | - | - | - | - | - | - | -693 K | -1.74 M | -783 K | - | -435 K | -293 K | -261 K | -435 K | -132 K | -1.44 M | -1.2 M | -132 K | -1.09 M | -2.88 M | -1.67 M | -1.09 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -132 K | -22.7 M | -5.76 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
ADMA Biologics
ADMA
|
50.4 M | $ 15.94 | -3.66 % | $ 3.8 B | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.51 | -3.31 % | $ 1.05 B |  Canada |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.84 | 1.57 % | $ 4.58 M | China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.16 | 1.51 % | $ 2.54 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
64 M | $ 75.6 | -1.22 % | $ 1.46 B | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.49 | -8.59 % | $ 380 M | Britain |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 162.3 | -1.08 % | $ 8.07 B | USA |
 |
BridgeBio Pharma
BBIO
|
-446 M | $ 65.02 | -2.29 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.09 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.77 | -1.42 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 60.51 | 0.13 % | $ 11.6 B | USA |
 |
Equillium
EQ
|
-21.8 M | $ 1.75 | - | $ 60.8 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.27 | -1.19 % | $ 1.36 B | Britain |
 |
Cabaletta Bio
CABA
|
-53.5 M | $ 3.21 | -6.52 % | $ 3.75 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-224 M | $ 3.01 | -5.94 % | $ 1.08 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 25.27 | -0.9 % | $ 677 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
142 M | $ 34.25 | -4.03 % | $ 3.56 B | USA |